PSNL News and Press, Personalis Inc. From 11/07/23

2023-11-07 16:04:47 ET More on Personalis Personalis: Collaborations Should Ignite Growth Narrative Personalis Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Personalis Historical earnings data for Personalis For further details see: ...

Increased third quarter revenue 23% to $18.2 million and increased full year guidance Presented data supporting NeXT Personal’s market leading sensitivity for cancer recurrence detection Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision on...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Personalis Inc. (PSNL) is expected to report $-0.54 for Q3 2023

NeXT Personal Dx is an ultra-sensitive test for detecting cancer from a blood sample Clinical data from groundbreaking TRACERx lung cancer study demonstrates significant sensitivity and lead time improvements in detecting cancer Personalis, Inc . (Nasdaq: PSNL), a leader i...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2023 financial results on Tuesday, November 7, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p...

NeXT Personal ® ctDNA assay shown to be more sensitive and predictive of clinical outcomes in early-stage lung cancer patients Demonstrates importance of an ultra-sensitive ctDNA approach Personalis, Inc . (Nasdaq: PSNL), a leader in precision oncology, today announ...

Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc . (Nasdaq: PSNL), a leader...

2023-09-06 08:27:34 ET Summary Personalis is a small-cap stock specializing in cancer genomics, with an advanced cancer diagnostics platform. The company reported significant losses in Q2 earnings but maintains a robust financial standing and expects future revenue growth. Per...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will present at the 21 st Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023 at 4:55 p.m. Eastern Time in New York, NY at the Sheraton...